Abstract
During the past several years, there has been intense research in the field of bone marrow-derived stem cell (BMSC) therapy to facilitate its translation into clinical setting. Although a lot has been accomplished, plenty of challenges lie ahead. Furthermore, there is a growing body of evidence showing that administration of BMSC-derived conditioned media (BMSC-CM) can recapitulate the beneficial effects observed after stem cell therapy. BMSCs produce a wide range of cytokines and chemokines that have, until now, shown extensive therapeutic potential. These paracrine mechanisms could be as diverse as stimulating receptor-mediated survival pathways, inducing stem cell homing and differentiation or regulating the anti-inflammatory effects in wounded areas. The current review reflects the rapid shift of interest from BMSC to BMSC-CM to alleviate many logistical and technical issues regarding cell therapy and evaluates its future potential as an effective regenerative therapy.
Highlights
The objective of stem cell regenerative therapy is to treat damaged organ tissues by avoiding the processes of cell death and/or inadvertent remodeled Tissue [1]
Understanding the therapeutic effects of regenerative therapy using bone marrow derived stem cell (BMSC) becomes more relevant when we look at the paracrine factors, which are secreted by BMSCs
In a separate but similar experiment, injections of the BMSC cytokines stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) increased numbers of circulating hematopoietic stem cells (HSC) to a level 250-fold greater than untreated myocardium
Summary
The objective of stem cell regenerative therapy is to treat damaged organ tissues by avoiding the processes of cell death and/or inadvertent remodeled Tissue [1]. Understanding the therapeutic effects of regenerative therapy using BMSCs becomes more relevant when we look at the paracrine factors, which are secreted by BMSCs. For example, the frequency of stem cell engraftment and the number of newly generated cardiomyocytes or vascular cells are too insignificant to represent the remarkable cardiac functional improvement attributed to fusion or. MSCs, which are commonly used in the lab, are present at a concentration several folds lower than their hematopoietic counterparts, representing approximately 0.01% of the total nucleated marrow cell population. They are separated from other cells in culture by their preferential attachment to plastic surfaces [13,14,15,16]. Differentiation of MSCs to cardiomyocyte-like cells has been observed in vitro under specific conditions and in vivo after injection into the myocardium [24,25,26,27]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
